{"groups":[{"description":"Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m\\^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m\\^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.","id":"FG000","title":"Trastuzumab + Taxane"},{"description":"Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"FG001","title":"Trastuzumab Emtansine + Placebo"},{"description":"Participants received trastuzumab emtansine plus pertuzumab. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the pertuzumab IV infusion, on Day 1 of each 3-week cycle. Pertuzumab was given as 840 mg IV on Day 1 of Cycle 1, then 420 mg IV on Day 1 of each subsequent 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"FG002","title":"Trastuzumab Emtansine + Pertuzumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"11"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"12"}],"type":"Reason not Specified"},{"reasons":[{"groupId":"FG000","numSubjects":"133"},{"groupId":"FG001","numSubjects":"144"},{"groupId":"FG002","numSubjects":"143"}],"type":"Sponsor Decision to Terminate Study"},{"reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"25"}],"type":"Subject/ Guardian Decision to Withdraw"},{"reasons":[{"groupId":"FG000","numSubjects":"170"},{"groupId":"FG001","numSubjects":"176"},{"groupId":"FG002","numSubjects":"169"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"365"},{"groupId":"FG001","numSubjects":"367"},{"groupId":"FG002","numSubjects":"363"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"355"},{"groupId":"FG001","numSubjects":"365"},{"groupId":"FG002","numSubjects":"360"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"365"},{"groupId":"FG001","numSubjects":"367"},{"groupId":"FG002","numSubjects":"363"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}